151 related articles for article (PubMed ID: 30234790)
1. Antituberculosis Drug-induced Liver Injury in Children: Incidence and Risk Factors During the Two-month Intensive Phase of Therapy.
Gafar F; Arifin H; Jurnalis YD; Yani FF; Fitria N; Alffenaar JC; Wilffert B
Pediatr Infect Dis J; 2019 Jan; 38(1):50-53. PubMed ID: 30234790
[TBL] [Abstract][Full Text] [Related]
2. Incidence, clinical features and impact on anti-tuberculosis treatment of anti-tuberculosis drug induced liver injury (ATLI) in China.
Shang P; Xia Y; Liu F; Wang X; Yuan Y; Hu D; Tu D; Chen Y; Deng P; Cheng S; Zhou L; Ma Y; Zhu L; Gao W; Wang H; Chen D; Yang L; He P; Wu S; Tang S; Lv X; Shu Z; Zhang Y; Yang Z; Chen Y; Li N; Sun F; Li X; He Y; Garner P; Zhan S
PLoS One; 2011; 6(7):e21836. PubMed ID: 21750735
[TBL] [Abstract][Full Text] [Related]
3. Incidence of antituberculosis-drug-induced hepatotoxicity and associated risk factors among tuberculosis patients in Dawro Zone, South Ethiopia: A cohort study.
Wondwossen Abera ; Waqtola Cheneke ; Gemeda Abebe
Int J Mycobacteriol; 2016 Mar; 5(1):14-20. PubMed ID: 26927985
[TBL] [Abstract][Full Text] [Related]
4. The association between HLA-DQB1 polymorphism and antituberculosis drug-induced liver injury: a Case-Control Study.
Chen R; Zhang Y; Tang S; Lv X; Wu S; Sun F; Xia Y; Zhan SY
J Clin Pharm Ther; 2015 Feb; 40(1):110-5. PubMed ID: 25250564
[TBL] [Abstract][Full Text] [Related]
5. The role of regular liver function monitoring in antituberculosis drug-induced liver injury.
Chang TE; Huang YS; Su WJ; Perng CL; Huang YH; Hou MC
J Chin Med Assoc; 2019 Jul; 82(7):535-540. PubMed ID: 31274784
[TBL] [Abstract][Full Text] [Related]
6. Possible association of HMOX1 and NQO1 polymorphisms with anti-tuberculosis drug-induced liver injury: A matched case-control study.
Yang M; Zhang H; Tao B; Pan H; Lu L; Yi H; Tang S
J Clin Pharm Ther; 2019 Aug; 44(4):534-542. PubMed ID: 30776144
[TBL] [Abstract][Full Text] [Related]
7. Revised Antituberculosis Drug Doses and Hepatotoxicity in HIV Negative Children.
Indumathi CK; Sethuraman A; Jain S; Krishnamurthy S
Indian J Pediatr; 2019 Mar; 86(3):229-232. PubMed ID: 30515702
[TBL] [Abstract][Full Text] [Related]
8. Transforming growth factor-beta 1 polymorphisms and anti-tuberculosis drug-induced liver injury. Polymorphisms in TGFβ1 and its relationship with anti-tuberculosis drug-induced liver injury.
Wu S; Wang Y; Zhang M; Wang M; He JQ
Therapie; 2019 Jun; 74(3):399-406. PubMed ID: 30093157
[TBL] [Abstract][Full Text] [Related]
9. Changing Trajectories of Alanine Aminotransferase and Risk of Antituberculosis Drug-Induced Liver Injury in Chinese Patients: A Cohort Study.
Chen X; Pan H; Hao Z; Yi H; Tang S
J Clin Pharmacol; 2024 Jul; 64(7):840-848. PubMed ID: 38436510
[TBL] [Abstract][Full Text] [Related]
10. Association of ABO blood group and antituberculosis drug-induced liver injury: A case-control study from a Chinese Han population.
Tao B; Yang M; Chen H; Pan H; Liu W; Yi H; Tang S
J Clin Pharm Ther; 2020 Aug; 45(4):638-645. PubMed ID: 32259340
[TBL] [Abstract][Full Text] [Related]
11. Hepatotoxicity Due to Antituberculosis Therapy among Paediatric Patients Seen at the University of Ilorin Teaching Hospital, North Central Nigeria.
Aishatu G; Rasheedah I; Wahab J; Sheni M; Damilola O; Adeniyi O
Ethiop J Health Sci; 2017 Mar; 27(2):115-120. PubMed ID: 28579706
[TBL] [Abstract][Full Text] [Related]
12. NAT2 polymorphisms and susceptibility to anti-tuberculosis drug-induced liver injury: a meta-analysis.
Wang PY; Xie SY; Hao Q; Zhang C; Jiang BF
Int J Tuberc Lung Dis; 2012 May; 16(5):589-95. PubMed ID: 22409928
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of risk factors for antituberculosis treatment induced hepatotoxicity.
Singla R; Sharma SK; Mohan A; Makharia G; Sreenivas V; Jha B; Kumar S; Sarda P; Singh S
Indian J Med Res; 2010 Jul; 132():81-6. PubMed ID: 20693595
[TBL] [Abstract][Full Text] [Related]
14. Preventive use of hepatoprotectors yields limited efficacy on the liver toxicity of anti-tuberculosis agents in a large cohort of Chinese patients.
Wu S; Xia Y; Lv X; Tang S; Yang Z; Zhang Y; Wang X; Hu D; Liu F; Yuan Y; Tu D; Sun F; Zhou L; Zhan S
J Gastroenterol Hepatol; 2015 Mar; 30(3):540-5. PubMed ID: 25160904
[TBL] [Abstract][Full Text] [Related]
15. Association of UGT2B7 polymorphisms with risk of induced liver injury by anti-tuberculosis drugs in Chinese Han.
Chen G; Wu SQ; Feng M; Wang Y; Wu JC; Ji GY; Zhang MM; Liu QQ; He JQ
Int J Immunopathol Pharmacol; 2017 Dec; 30(4):434-438. PubMed ID: 28934901
[TBL] [Abstract][Full Text] [Related]
16. Hepatic enzyme abnormalities in children on triple therapy for tuberculosis.
Corrigan D; Paton J
Pediatr Pulmonol; 1999 Jan; 27(1):37-42. PubMed ID: 10023790
[TBL] [Abstract][Full Text] [Related]
17. Association of LEPR polymorphisms with predisposition and inflammatory response in anti-tuberculosis drug-induced liver injury: A pilot prospective investigation in Western Chinese Han population.
Zhao Z; Peng W; Zhou J; Zhou Y; Liu T; Bai H; Wu Q; Song J; Wu L; Song X; Ying B
Infect Genet Evol; 2019 Nov; 75():103970. PubMed ID: 31325611
[TBL] [Abstract][Full Text] [Related]
18. Antituberculosis drugs and hepatotoxicity.
Yew WW; Leung CC
Respirology; 2006 Nov; 11(6):699-707. PubMed ID: 17052297
[TBL] [Abstract][Full Text] [Related]
19. Absence of significant association between UGT2B4 genetic variants and the susceptibility to anti-tuberculosis drug-induced liver injury in a Western Chinese population.
Chen H; Jiao L; Zhou J; Bai H; Lyu M; Wu T; Wu L; Song J; Liu T; Yan H; Ying B
J Clin Pharm Ther; 2021 Feb; 46(1):66-73. PubMed ID: 32170986
[TBL] [Abstract][Full Text] [Related]
20. Antituberculosis drug-induced liver injury in chronic hepatitis and cirrhosis.
Park WB; Kim W; Lee KL; Yim JJ; Kim M; Jung YJ; Kim NJ; Kim DH; Kim YJ; Yoon JH; Oh MD; Lee HS
J Infect; 2010 Oct; 61(4):323-9. PubMed ID: 20670648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
